Incyte Corporation (INCY) Stock Analysis
Healthcare · Biotechnology
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and... Read more
TrendMatrix rates Incyte Corporation (INCY) as Buy (Wait for Entry) with high confidence. The stock trades at $92.23 with +8.1% upside to the $99.73 price target. Overall score: 6.7/10 across 10 analysis dimensions. Reward/risk ratio: 1.3:1.
Passes 2/4 gates (clean insider activity, no SEC red flags). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Incyte Corporation (INCY) as Buy (Wait for Entry) with high confidence. Score 6.7/10. Entry target: $91.03.
Take-profit target: $99.73 (+8.1% upside). Reward/risk ratio: 1.3:1. Stop-loss: $86.57.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5; Negative momentum.
Incyte Corporation trades at a P/E of 14.1 (forward 10.5). TrendMatrix value score: 7.6/10. Verdict: Buy (Wait for Entry).
33 analysts cover INCY with a consensus score of 3.8/5. Average price target: $108.
What does Incyte Corporation do?Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of...
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.